Last reviewed · How we verify
Comparator: placebo, losartan, hydrochlorothiazide
This drug is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release.
This drug is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release. Used for Hypertension, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Comparator: placebo, losartan, hydrochlorothiazide |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Angiotensin II receptor blockers selectively antagonize AT1 receptors on vascular smooth muscle and adrenal tissue, preventing the vasoconstrictive and sodium-retaining effects of angiotensin II. This results in vasodilation and reduced blood volume, leading to decreased blood pressure. ARBs are commonly compared to other antihypertensive classes like thiazide diuretics (hydrochlorothiazide) and ACE inhibitors in clinical trials.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Diarrhea
- Upper respiratory tract infection
Key clinical trials
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
- MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) (PHASE3)
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
- Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) (PHASE3)
- Obese Hypertension Study (0954-315) (PHASE3)
- MK-0954E Study in Participants With Hypertension (MK-0954E-357) (PHASE3)
- A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: